Fosun Pharma Of China Gets $47 Million World Bank Loan To Expand
This article was originally published in PharmAsia News
China's Fosun Pharma, a major supplier of malaria drugs to emerging markets, is to receive a $47 million loan from part of the World Bank Group to fund an expansion of business.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.